Neovasc Inc. Stock News

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 24, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") has received written notificatio…

VANCOUVER and MINNEAPOLIS, Nov. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") ( NASDAQ , TSX : NVCN) has received written notification (the "Nasdaq Notice") from the Nasdaq Stock Market LLC ("Nasdaq") informing the Company that in accordance with Nasdaq Listing Rule 5810(c)(3)(A), Nasdaq has granted an additional 180 calendar day period within which to evidence compliance with the $1.00 bid price requirement following the expiration of the current compliance period on November 22, 2021.

Neovasc Inc. (NASDAQ:NVCN) (TSE:NVC) was the target of a significant increase in short interest in October. As of October 29th, there was short interest totalling 622,100 shares, an increase of 23.6% from the October 14th total of 503,200 shares. Based on an average trading volume of 450,000 shares, the days-to-cover ratio is presently 1.4 days. []

Neovasc Inc. (NASDAQ:NVCN) (TSE:NVC) saw a significant increase in short interest in October. As of October 29th, there was short interest totalling 622,100 shares, an increase of 23.6% from the October 14th total of 503,200 shares. Based on an average daily trading volume, of 450,000 shares, the short-interest ratio is currently 1.4 days. Currently, 0.9% []

Global Transcatheter Aortic Valve Replacement (TAVR) Market Synopsis: DBMR team offers customization of Transcatheter Aortic Valve Replacement (TAVR) Market report according to the business needs. Contact sales team, who will guarantee to get a report that suits the necessities. The Market

Neovasc Inc. (NVCN) CEO Fred Colen on Q3 2021 Results - Earnings Call Transcript

VANCOUVER, Nov. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire –  Neovasc Inc. (NASDAQ, TSX: NVCN), will report financial results for the quarter ended September 30, 2021 on Tuesday, November 9, 202

VANCOUVER and MINNEAPOLIS, Sept. 28, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the publication of an article

The FDA approved the Investigational Device Exemption for Neovasc Inc's (NASDAQ:NVCN) COSIRA-II IDE Clinical Trial regarding the Neovasc Reducer. Related Content:   Real-World Study Shows Neovasc

Company on Schedule to Commence Trial Late This Year

VANCOUVER and MINNEAPOLIS, Aug. 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire –  Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ,TSX: NVCN) today announced that its management team will

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 17, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has filed a

Neovasc (NVCN) delivered earnings and revenue surprises of 0.00% and -36.70%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Neovasc Inc. (NVCN) CEO Fred Colen on Q2 2021 Results - Earnings Call Transcript

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 10, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for